<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02805049</url>
  </required_header>
  <id_info>
    <org_study_id>LOCAL/2016/CR-01</org_study_id>
    <nct_id>NCT02805049</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study on Echinocandins for Patients With Septic Shock Following Secondary Peritonitis</brief_title>
  <official_title>Pharmacokinetic Study on Echinocandins for Patients With Septic Shock Following Secondary Peritonitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to describe the pharmacokinetics of the prescribed
      echinocandins for septic shock with secondary peritonitis for which intra-abdominal fungal
      infection is suspected or proven.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objectives of this study are:

        -  Determine whether the current recommended doses of caspofungin achieve the
           Pharmacokinetic/Pharmacodynamic (PK/PD) target for this molecule.

        -  Determine whether the current recommended doses of micafungin achieve the PK / PD target
           for this molecule

        -  Describe the peritoneal concentrations of echinocandins in secondary peritonitis
           complicated with septic shock

        -  Identify via modeling PK / PD parameters and based on monte Carlo simulations the
           optimal dosing regimen for caspofungin and micafungin in this population
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 28, 2017</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antifungal treatment plasmatic clearance (L/h)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antifungal treatment plasmatic clearance (L/h)</measure>
    <time_frame>Days 3-5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The volume of distribution (L) corresponding to plasmatic antifungal treatment concentration</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The volume of distribution (L) corresponding to plasmatic antifungal treatment concentration</measure>
    <time_frame>Days 3-5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Intercompartmental transfer constant for a bi-compartmental model for plasmatic antifungal treatment concentration</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Intercompartmental transfer constant for a bi-compartmental model for plasmatic antifungal treatment concentration</measure>
    <time_frame>Days 3-5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The area under the curve for plasmatic antifungal treatment concentrations</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The area under the curve for plasmatic antifungal treatment concentrations</measure>
    <time_frame>Days 3-5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The maximum concentration for plasmatic antifungal treatment concentrations</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The maximum concentration for plasmatic antifungal treatment concentrations</measure>
    <time_frame>Days 3-5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The minimum concentration for plasmatic antifungal treatment concentrations</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The minimum concentration for plasmatic antifungal treatment concentrations</measure>
    <time_frame>Days 3-5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The target Pharmacokinetic/Pharmacodynamic ratio for caspofungin</measure>
    <time_frame>Day 1</time_frame>
    <description>corresponds to: area under the curve / minimum inhibitory concentration &gt;865</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The target Pharmacokinetic/Pharmacodynamic ratio for caspofungin</measure>
    <time_frame>Days 3-5</time_frame>
    <description>corresponds to: area under the curve / minimum inhibitory concentration &gt;865</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The target Pharmacokinetic/Pharmacodynamic ratio for micafungin</measure>
    <time_frame>Day 1</time_frame>
    <description>corresponds to: area under the curve / minimum inhibitory concentration &gt;285 et 3000</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The target Pharmacokinetic/Pharmacodynamic ratio for micafungin</measure>
    <time_frame>Days 3-5</time_frame>
    <description>corresponds to: area under the curve / minimum inhibitory concentration &gt;285 et 3000</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The area under the curve for peritoneal antifungal treatment concentrations</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The area under the curve for peritoneal antifungal treatment concentrations</measure>
    <time_frame>Days 3-5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The maximum concentration for peritoneal antifungal treatment concentrations</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The maximum concentration for peritoneal antifungal treatment concentrations</measure>
    <time_frame>Days 3-5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The minimum concentration for peritoneal antifungal treatment concentrations</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The minimum concentration for peritoneal antifungal treatment concentrations</measure>
    <time_frame>Days 3-5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The probability of attaining the targeted Pharmacokinetic/Pharmacodynamic ratio</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The probability of attaining the targeted Pharmacokinetic/Pharmacodynamic ratio</measure>
    <time_frame>Days 3-5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The fraction of the probability of attaining the targeted Pharmacokinetic/Pharmacodynamic ratio</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The fraction of the probability of attaining the targeted Pharmacokinetic/Pharmacodynamic ratio</measure>
    <time_frame>Days 3-5</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Septic Shock</condition>
  <condition>Peritonitis</condition>
  <arm_group>
    <arm_group_label>The study population</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study population consisted of patients admitted to the ICU for septic shock associated with secondary peritonitis and requiring antifungal therapy via echinocandins (micafungin or caspofungin).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Echinocandins</intervention_name>
    <description>The patients included in this protocol require routine treatment with caspofungin or micafungin. Though this intervention is under study, it is not modified by this protocol.</description>
    <arm_group_label>The study population</arm_group_label>
    <other_name>caspofungin or micafungin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The emergency inclusion procedure was correctly applied according to French law
             (signature of consent form by a patient-designated trusted person or a family member,
             or a medical decision to proceed with patient inclusion if the latter two persons are
             unavailable) ---- OR ---- signature of the consent form by the patient

          -  The patient must be insured or beneficiary of a health insurance plan

          -  The patient is 18 years of age or older

          -  The patient has beed admitted to the ICU for septic shock accompanying secondary
             peritonitis

          -  Patient requiring antifungal treatment via echinocandins (caspofungin or micafungin)

          -  A venous or arterial access for blood sampling is already in place for routine care

        Exclusion Criteria:

          -  The patient is participating in an interventional study that may affect the results of
             the present study, or has participated in such a study within the past 3 months

          -  The patient is under judicial protection, or is an adult under guardianship

          -  The patient is pregnant, parturient or breastfeeding

          -  Moribund patient

          -  Known positive serology for human immunodeficiency virus (HIV)

          -  Known positive serology for hepatitis C

          -  Known diagnosis for tuberculosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claire Roger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nîmes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claire Roger, MD</last_name>
    <phone>+33.(0)4.66.68.30.50</phone>
    <email>claire.roger@chu-nimes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carey Suehs, PhD</last_name>
    <phone>+33.(0)4.66.68.67.88</phone>
    <email>carey.suehs@chu-nimes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Brisbane Women's Hospital</name>
      <address>
        <city>Herston</city>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes - Hôpital Universitaire Carémeau</name>
      <address>
        <city>Nîmes Cedex 09</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Claire Roger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Yves Lefrant, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillaume Louart, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin Louart, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline Boutin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Saber Barbar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent Muller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pablo Massenet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aurélien Daurat, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287.</citation>
    <PMID>26903338</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2016</study_first_submitted>
  <study_first_submitted_qc>June 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2016</study_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Peritonitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Micafungin</mesh_term>
    <mesh_term>Caspofungin</mesh_term>
    <mesh_term>Echinocandins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

